Skip to content
Screener

Aquestive Therapeutics, Inc. AQST Proceeds from issuance of common stock under public equity offering-ATM, net

Proceeds from issuance of common stock under public equity offering-ATM, net at other companies

Lightbridge logo
LightbridgeLTBR
$45.49M+707%
Lightbridge logo
LightbridgeLTBR
$45.49M+707%
EMP
Empery DigitalEMPD
$24.79M
EMP
Empery DigitalEMPD
$24.79M
GTY
Getty RealtyGTY
$48.3M+20,225%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$16.4M+50.7%

Other financials

Income statement

See full
Revenue$13.8M+38.1%
Gross profit$9.8M+80.1%
Operating income-$8.2M+27.7%
Net income-$22.9M-68.8%
EPS (diluted)-$0.18-28.6%

Balance sheet

See full
Cash & equivalents$98.5M+62.7%
Total debt$63.4M+6.0%
Total equity-$56.6M+22.0%
Total assets$132.1M+41.0%

Cash flow

See full
Operating cash flow-$9.4M-19.3%
CapEx$212.0K+98.1%
Free cash flow-$9.7M-20.3%

Valuation

See full
Market cap$538.25M+40.4%
Enterprise value$503.14M+31.5%
P/S10×+1.3×

Profitability

See full
Gross margin67%+5.9pp
Operating margin-97.5%-15.0pp
Net margin-144.6%-2.6pp
FCF margin-85%-17.0pp

Returns & leverage

See full
Return on equity121.1%
Debt / equity-1.1×
Current ratio7.2×+3.7×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept aqst:ProceedsFromIssuanceOfPublicOfferingIssuanceOfWarrantsAndWarrantExercises.

The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026. Open the filing →

Filed
May 13, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001398733-26-000030

FAQ

What is Aquestive Therapeutics, Inc.'s proceeds from issuance of common stock under public equity offering-atm, net?
Aquestive Therapeutics, Inc. (AQST) reported proceeds from issuance of common stock under public equity offering-atm, net of $4.76M in Q1 2026.
How has Aquestive Therapeutics, Inc.'s proceeds from issuance of common stock under public equity offering-atm, net changed year-over-year?
Aquestive Therapeutics, Inc.'s proceeds from issuance of common stock under public equity offering-atm, net decreased by 77.7% year-over-year, from $21.36M to $4.76M.
What is the long-term trend for Aquestive Therapeutics, Inc.'s proceeds from issuance of common stock under public equity offering-atm, net?
Over 3 years (2021 to 2024), Aquestive Therapeutics, Inc.'s proceeds from issuance of common stock under public equity offering-atm, net has grown at a -26.6% compound annual growth rate (CAGR), from $29.78M to $11.78M.
What does proceeds from issuance of common stock under public equity offering-atm, net mean?
Proceeds from issuance of common stock under public equity offering-ATM, net as reported by Aquestive Therapeutics, Inc. Common Stock.

Ask your AI about Aquestive Therapeutics, Inc.'s proceeds from issuance of common stock under public equity offering-atm, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude